Recent Insider Transactions • Jul 08
Co-Founder recently sold US$155k worth of stock On the 1st of July, Paul Badawi sold around 29k shares on-market at roughly US$5.42 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Paul has been a net seller over the last 12 months, reducing personal holdings by US$771k. Recent Insider Transactions Derivative • Jul 02
Co-Founder notifies of intention to sell stock Paul Badawi intends to sell 29k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of July. If the sale is conducted around the recent share price of US$5.42, it would amount to US$155k. For the year to December 2020, Paul's total compensation was 33% salary and 67% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Paul currently holds 5.54m shares (0.1019112095359337 of the company). Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months. Board Change • Jul 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Gary Burbach was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions Derivative • May 19
Chief Operating Officer notifies of intention to sell stock Alison Bauerlein intends to sell 13k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of May. If the sale is conducted around the recent share price of US$5.12, it would amount to US$65k. Since June 2025, Alison's direct individual holding has increased from 99.56k shares to 156.79k. Company insiders have collectively sold US$724k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • May 07
First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2026 results: US$0.24 loss per share (improved from US$0.28 loss in 1Q 2025). Revenue: US$19.7m (up 13% from 1Q 2025). Net loss: US$13.0m (loss narrowed 8.3% from 1Q 2025). Revenue exceeded analyst estimates by 6.2%. Earnings per share (EPS) missed analyst estimates by 38%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 23
Sight Sciences, Inc., Annual General Meeting, Jun 04, 2026 Sight Sciences, Inc., Annual General Meeting, Jun 04, 2026. Tillkännagivande • Apr 22
Sight Sciences, Inc. to Report Q1, 2026 Results on May 06, 2026 Sight Sciences, Inc. announced that they will report Q1, 2026 results After-Market on May 06, 2026 Recent Insider Transactions Derivative • Apr 07
Co-Founder notifies of intention to sell stock Paul Badawi intends to sell 29k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of April. If the sale is conducted around the recent share price of US$3.70, it would amount to US$108k. For the year to December 2020, Paul's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2025, Paul's direct individual holding has increased from 5.30m shares to 5.52m. Company insiders have collectively sold US$458k more than they bought, via options and on-market transactions in the last 12 months. Tillkännagivande • Apr 02
Sight Sciences Inc Features Interventional Technologies for Glaucoma and Dry Eye Disease At the American Society of Cataract and Refractive Surgery Annual Meeting Sight Sciences, Inc. announced that data on two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System and the TearCare System, will be presented at the American Society of Cataract and Refractive Surgery Annual Meeting held in Washington, DC. TearCare System Oral and Poster Presentations: Outcomes for Localized Heat Therapy (LHT) or Cyclosporine in Dry Eye Disease (DED) Signs and Symptoms by Baseline Severity, April 11, at the Walter E. Washington Convention Center – Level 2, 209B. Clinically Relevant Change in Tear Break-up Time (TBUT) with Localized Heat Therapy or Cyclosporine in Dry Eye Disease (DED) – poster presentation. OMNI Surgical System Poster Presentation: Longer-term Diurnal IOP (DIOP) Fluctuations Following Canaloplasty and Trabeculotomy (CT) with and without cataract surgery – poster presentation. The OMNI Surgical System and OMNI Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. The SION Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The TearCare System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services. Price Target Changed • Mar 12
Price target decreased by 8.8% to US$8.83 Down from US$9.68, the current price target is an average from 6 analysts. New target price is 144% above last closing price of US$3.62. Stock is up 51% over the past year. The company is forecast to post a net loss per share of US$0.55 next year compared to a net loss per share of US$0.74 last year. Reported Earnings • Mar 06
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: US$0.74 loss per share (improved from US$1.03 loss in FY 2024). Revenue: US$77.4m (down 3.1% from FY 2024). Net loss: US$38.4m (loss narrowed 25% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.0%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 05
Sight Sciences Provides Earnings Guidance for the Full Year 2026 Sight Sciences provided earnings guidance for the full year 2026. For the year, the company expects revenue to range from $82 million to $88 million, representing growth of 6% to 14% compared to full year 2025. This revenue guidance includes Interventional Glaucoma segment revenue of $77 million to $81 million, representing growth of 2% to 7% and Interventional Dry Eye segment revenue of $5 million to $7 million, compared to $1.6 million in 2025. Tillkännagivande • Feb 19
Sight Sciences, Inc. to Report Q4, 2025 Results on Mar 04, 2026 Sight Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 04, 2026 Recent Insider Transactions • Jan 22
Co-Founder recently sold US$148k worth of stock On the 16th of January, Paul Badawi sold around 22k shares on-market at roughly US$6.62 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$277k. Paul has been a net seller over the last 12 months, reducing personal holdings by US$661k. Recent Insider Transactions Derivative • Jan 18
Co-Founder notifies of intention to sell stock Paul Badawi intends to sell 22k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of January. If the sale is conducted around the recent share price of US$6.62, it would amount to US$148k. For the year to December 2020, Paul's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Paul's direct individual holding has decreased from 6.03m shares to 5.93m. Company insiders have collectively sold US$318k more than they bought, via options and on-market transactions in the last 12 months. Tillkännagivande • Jan 13
Sight Sciences Announces Earnings Guidance for Fourth Quarter and Full Year Ended December 31, 2025 Sight Sciences announced earnings guidance for Fourth Quarter and full year ended December 31, 2025 . For the fourth quarter 2025, total revenue is expected to be in the range of $20.3 million to $20.4 million, an increase of 7% at the estimated midpoint compared to the prior year period.
For the Full year 2025, total revenue is expected to be in the range of $77.3 million to $77.4 million, a decrease of 3% at the estimated midpoint compared to the prior year. Recent Insider Transactions • Jan 11
Co-Founder recently sold US$277k worth of stock On the 6th of January, Paul Badawi sold around 37k shares on-market at roughly US$7.45 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Paul has been a net seller over the last 12 months, reducing personal holdings by US$585k. Recent Insider Transactions Derivative • Jan 04
Co-Founder notifies of intention to sell stock Paul Badawi intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of January. If the sale is conducted around the recent share price of US$7.43, it would amount to US$188k. For the year to December 2020, Paul's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Paul's direct individual holding has decreased from 6.03m shares to 5.96m. Company insiders have collectively bought US$195k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions • Dec 21
Independent Chairman recently bought US$116k worth of stock On the 16th of December, Staffan Encrantz bought around 14k shares on-market at roughly US$8.31 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of US$1.3m worth in shares. Price Target Changed • Dec 11
Price target increased by 19% to US$7.25 Up from US$6.08, the current price target is an average from 6 analysts. New target price is 12% below last closing price of US$8.28. Stock is up 123% over the past year. The company is forecast to post a net loss per share of US$0.74 next year compared to a net loss per share of US$1.03 last year. Recent Insider Transactions Derivative • Nov 28
Insider exercised options and sold US$274k worth of stock On the 25th of November, Jeremy Hayden exercised 45k options at a strike price of around US$1.96 and sold these shares for an average price of US$8.08 per share. This trade did not impact their existing holding. Since March 2025, Jeremy's direct individual holding has decreased from 284.88k shares to 256.59k. Company insiders have collectively bought US$38k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions • Nov 20
Insider recently sold US$102k worth of stock On the 17th of November, Brenton Taylor sold around 14k shares on-market at roughly US$7.06 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.7m more than they bought in the last 12 months. Major Estimate Revision • Nov 13
Consensus estimates of losses per share improve by 30% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$74.7m to US$77.7m. EPS estimate increased from -US$0.971 per share to -US$0.685 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target up from US$4.67 to US$6.08. Share price rose 53% to US$7.72 over the past week. Tillkännagivande • Nov 12
Sight Sciences, Inc. Announces the Results from Three Key Publishes Publishes Managed Manages That Further Demonstrates the Value of an Interventional Treatment in Treating Glaucoma Sight Sciences, Inc. announced the results from three key published manuscripts that further demonstrate the value of an interventional mindset in treating glaucoma. The following are notable results from the studies: In a 24-month prospective study of 18 eyes with medication washout at baseline, 12 and 24 months, of standalone OMNI use, mean baseline IOP of 26.1 mmHg was reduced an average of 9.7mmHg at 12 months and 10.6 mmHg at 24 months (both p1; In a retrospective, observational study of nearly 13,000 African American eyes (including 12,057 cataract surgery only, 491 iStent inject®?, 189 Hydrus®? Microstent, and 91 OMNI - all minimally invasive glaucoma surgery (MIGS) at the time of cataract surgery), IOP reductions were higher in this study's MIGS plus cataract surgery cohorts than cataract surgery alone; the proportion of patients with a greater than or equal to 20% reduction in IOP from baseline was greatest for OMNI, followed by Hydrus Microstent and iStent injection. In a subgroup analysis of 220 eyes that had undergone a standalone OMNI procedure in primary open-angle glaucoma, including mild, moderate and severe patients, and both phakic and pseudophakic eyes, IOP was significantly reduced for up to 3 years regardless of lens status or disease severity. Reported Earnings • Nov 07
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: US$0.16 loss per share (improved from US$0.22 loss in 3Q 2024). Revenue: US$19.9m (down 1.2% from 3Q 2024). Net loss: US$8.17m (loss narrowed 26% from 3Q 2024). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Tillkännagivande • Oct 24
Sight Sciences, Inc. to Report Q3, 2025 Results on Nov 06, 2025 Sight Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025 Price Target Changed • Oct 22
Price target increased by 7.7% to US$4.67 Up from US$4.33, the current price target is an average from 6 analysts. New target price is 9.0% below last closing price of US$5.13. Stock is down 5.2% over the past year. The company is forecast to post a net loss per share of US$0.97 next year compared to a net loss per share of US$1.03 last year. Tillkännagivande • Oct 17
Sight Sciences, Inc. Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare Interventional Dry Eye Procedure Sight Sciences, Inc. announced that two Medicare Administrative Contractors (MACs), Novitas Solutions, Inc. (Novitas) and First Coast Service Options, Inc. (FCSO), each established jurisdiction-wide pricing for CPT®? code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual expression, bilateral), which describes the procedure performed with the Company's TearCare®? System and related accessories (TearCare). The Medicare fee schedule amount is effective for dates of service on and after January 1, 2025, in all Novitas and FCSO jurisdictions and localities. The established local fee schedule amount for CPT code 0563T is active for claim processing and is expected to be published on the Novitas and FCSO websites for reference by eyecare providers in these areas. TearCare procedure claims will be payable by First Coast and Novitas in the areas administered by them based on individual medical necessity determinations. The states and regions covered by these two MACS have 10.4 million in estimated total covered lives and represents approximately 30% of the total Medicare fee-for-service covered lives. Sight Sciences recently launched the Sight Access Portal, which is available to provide assistance to all TearCare®? System, OMNI®? Surgical System, and SION®? Surgical Instrument providers with patient benefit verification, assistance with prior authorizations, predeterminations, and any reimbursement questions. Recent Insider Transactions • Oct 05
Co-Founder recently sold US$82k worth of stock On the 1st of October, Paul Badawi sold around 24k shares on-market at roughly US$3.34 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Paul has been a net seller over the last 12 months, reducing personal holdings by US$352k. Recent Insider Transactions Derivative • Oct 02
Co-Founder notifies of intention to sell stock Paul Badawi intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of October. If the sale is conducted around the recent share price of US$3.34, it would amount to US$82k. For the year to December 2020, Paul's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2024, Paul's direct individual holding has increased from 5.73m shares to 5.99m. Company insiders have collectively sold US$1.9m more than they bought, via options and on-market transactions in the last 12 months. Tillkännagivande • Sep 17
Sight Sciences, Inc. Announces Publication of A Systematic Literature Review and Meta- Analysis Showing OMNI Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use Sight Sciences, Inc. announced the results as published in the European Journal of Ophthalmology of a systematic review and meta-analysis of the clinical effectiveness, safety, humanistic and economic impact of the OMNI Surgical System (OMNI). The study assessed OMNI, as well as its predecessors, Visco360 and Trab360, for the treatment of open-angle glaucoma (OAG). The paper reports both standalone and combined treatments to be effective in achieving long-term, clinically significant reductions in intraocular pressure (IOP) and medication use, with sustained improvements over time. OMNI significantly reduced IOP, with mean IOP below 18 mmHg (range of 11.5 to 17.2 mmHg for patients with baseline IOP 18 mmHg and 12.8 to 15.4 mmHg for patients with base IOP ®?. The cost-utility analysis included quality of life (QoL) outcomes in the form of quality-adjusted life years (QALYs). The average QALYs per patient treated with OMNI were 8.95 over a lifetime horizon and 1.59 over two years, compared with 8.93 and 1.58 for iStent inject. The slightly higher QALYs for OMNI were attributed to its favorable adverse event profile. New Risk • Sep 08
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$259k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$41m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$259k sold). Tillkännagivande • Aug 30
Matthew Link to Step Down as the Sight Sciences, Inc.’s Chief Commercial Officer Effective August 31, 2025, Matthew Link will step down as the Company’s Chief Commercial Officer to pursue other opportunities. The Company appreciates Mr. Link’s many contributions over the past years and his agreement to provide transition services on a consulting basis through September 30, 2025, or such later date as the Company may request and Mr. Link may agree to. Reported Earnings • Aug 11
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: US$0.23 loss per share (improved from US$0.25 loss in 2Q 2024). Revenue: US$19.6m (down 8.5% from 2Q 2024). Net loss: US$11.9m (loss narrowed 3.1% from 2Q 2024). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Major Estimate Revision • Aug 10
Consensus estimates of losses per share improve by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$73.5m to US$74.7m. EPS estimate increased from -US$1.10 per share to -US$0.947 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target up from US$3.93 to US$4.27. Share price rose 30% to US$4.24 over the past week. New Risk • Aug 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$37m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change). Price Target Changed • Aug 08
Price target increased by 13% to US$4.27 Up from US$3.77, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of US$4.24. Stock is down 29% over the past year. The company is forecast to post a net loss per share of US$0.95 next year compared to a net loss per share of US$1.03 last year. Tillkännagivande • Aug 08
Sight Sciences, Inc. Raises Revenue Guidance for the Full Year 2025 Sight Sciences, Inc. raised revenue guidance for the full year 2025. For the year, the company raised revenue guidance expectations to $72.0 million to $76.0 million, representing a 5% to 10% decline compared to full year 2024 revenue, versus prior revenue guidance of $70.0 million to $75.0 million. Tillkännagivande • Jul 30
Sight Sciences, Inc. Announces the Results of A Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the Tearcare®? System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease Sight Sciences, Inc. announced the results of a cost-utility analysis (CUA) assessing the cost-effectiveness of the TearCare®? System compared to cyclosporine 0.05% (CsA) for the treatment of moderate to severe meibomian gland disease (MGD) associated dry eye disease (DED). The analysis, published ahead of print in Expert Review of Pharmacoeconomics and Outcomes Research, demonstrated that TearCare is not only associated with greater health utility over time but also resulted in significant cost savings compared to CsA, offering a more efficient and patient-centric approach to treating this common ocular disease. The analysis, conducted from a US healthcare payer perspective using a 1-year time horizon, revealed that TearCare resulted in lower per-patient annual costs ($4,916) and higher quality-adjusted life years (QALYs; 0.76) compared to CsA ($5,819 and 0.74 QALYs, respectively). This translated to per-patient annual cost savings of $903 and an incremental benefit of 0.014 QALYs. Tillkännagivande • Jul 29
Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare Procedure for the Treatment of Dry Eye Disease Sight Sciences, Inc. announced that the manuscript detailing 24-month results from Stage 3 of the SAHARA randomized controlled trial (RCT) has been published ahead of print (PAP) by Optometry and Vision Science (Official Journal of the American Academy of Optometry) and is available online in pre-publication format. All mean signs and symptoms remained statistically significantly better than the study baseline at all time points measured through the end of the study at 24 months. The majority (66%) of participants who received treatment for dry eye disease (DED) with the TearCare®? System (TearCare) at baseline and again at Month 5 required no additional treatment based on pre-defined retreatment criteria. SAHARA RCT 24-month Stage 3 Results: Tear breakup time (TBUT) remained statistically significantly better than study baseline for all subjects through Month 24 at all timepoints measured with means ranging from 6.29 to 7.13 seconds compared to the baseline of 4.41 seconds (all p; Meibum quality and quantity as measured by Meibomian Gland Secretion Score (MGSS) showed that the improvement from baseline observed at Month 6 following two TearCare treatments, 7.26 to 18.95, was maintained through 24 months for all subjects (means ranging from 17.68 to 18.95, p; The number of meibomian glands yielding any liquid (MGYAL) and number of glands yielding clear liquid (MGYCL) also showed clinically meaningful and statistically significant improvement at Month 6 which was sustained throughout the 24-month follow-up period at all timepoints measured, as did anesthetized Shirmer tear scores (STS) as well as conjunctival and corneal staining scores. Clin Ophthalmol. 2023;17:3925-3940. Ayers BD, Bloomenstein MR, Loh J, et al. Improved signs and symptoms of dry eye disease for Restasis®? patients following a single TearCare®? treatment: phase 2 of the SAHARA study. Tillkännagivande • Jul 25
Sight Sciences, Inc. to Report Q2, 2025 Results on Aug 07, 2025 Sight Sciences, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 Recent Insider Transactions • Jul 09
Co-Founder recently sold US$98k worth of stock On the 1st of July, Paul Badawi sold around 24k shares on-market at roughly US$4.15 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Paul has been a net seller over the last 12 months, reducing personal holdings by US$347k. Recent Insider Transactions Derivative • Jul 02
Co-Founder notifies of intention to sell stock Paul Badawi intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of July. If the sale is conducted around the recent share price of US$4.15, it would amount to US$98k. For the year to December 2020, Paul's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2024, Paul's direct individual holding has decreased from 5.73m shares to 5.30m. Company insiders have collectively sold US$1.9m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Jun 01
Independent Chairman recently bought US$452k worth of stock On the 29th of May, Staffan Encrantz bought around 128k shares on-market at roughly US$3.52 per share. This transaction amounted to 7.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Staffan has been a net seller over the last 12 months, reducing personal holdings by US$1.6m. Price Target Changed • May 22
Price target increased by 7.8% to US$3.68 Up from US$3.42, the current price target is an average from 6 analysts. New target price is 12% above last closing price of US$3.28. Stock is down 38% over the past year. The company is forecast to post a net loss per share of US$1.10 next year compared to a net loss per share of US$1.03 last year. Reported Earnings • May 09
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: US$0.28 loss per share (improved from US$0.33 loss in 1Q 2024). Revenue: US$17.5m (down 9.1% from 1Q 2024). Net loss: US$14.2m (loss narrowed 13% from 1Q 2024). Revenue exceeded analyst estimates by 6.0%. Earnings per share (EPS) also surpassed analyst estimates by 4.9%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Tillkännagivande • May 09
Sight Sciences Reaffirms Earnings Guidance for Full Year 2025 Sight Sciences reaffirms earnings guidance for full year 2025. For the year, the company expects revenue to be approximately $70.0 million to $75.0 million, representing a 6% to 12% decline compared to full year 2024 revenue. Tillkännagivande • Apr 23
Sight Sciences, Inc. Appoints Gerhard (Gary) F. Burbach as Board of Directors on April 21, 2025 Sight Sciences, Inc. announced that Gerhard (Gary) F. Burbach was appointed to the company’s board of directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. Mr. Burbach is a member of the Board of Directors and Chair of the Compensation Committee of BWX Technologies and Chairman of the Board of Directors of Procyrion Inc. He previously served as a member of the Board of Directors of Fluidigm Corporation, from 2013 to 2023, as Chairman of the Board of Directors of Artelon, Inc., from 2020 until its acquisition by Stryker Corporation in 2024, and as a member of the Board of Directors of Vascular Dynamics, Inc., from 2017 to 2024. From 2006 to 2014, Mr. Burbach was President, Chief Executive Officer and a member of the Board of Directors of Thoratec Corporation. Prior to that, he held executive leadership positions at Digirad Corporation, Philips Medical Systems, and ADAC Laboratories. Mr. Burbach also spent six years at McKinsey & Company, Inc., focused primarily on the firm’s healthcare practice. Mr. Burbach holds a Bachelor of Science in Industrial Engineering from Stanford University and a Master of Business Administration from Harvard Business School. Tillkännagivande • Apr 22
Sight Sciences, Inc. to Debut OMNI Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio Sight Sciences, Inc. announced the expansion of the OMNI product family by launching the OMNI Edge Surgical System. The new technology will debut at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, taking place April 25-27 in Los Angeles, California. OMNI Edge with TruSync technology builds on the proven performance of the OMNI Surgical System and introduces a higher-capacity viscoelastic delivery feature (21 uL) while maintaining the trusted safety, efficacy, and usability of the OMNI device. Designed for versatility in minimally invasive glaucoma surgery (MIGS), OMNI Edge reduces intraocular pressure (IOP) by treating all three known areas of resistance in theaqueous outflow system--the trabecular meshwork, Schlemm's canal, and the collector channels. The system is adaptable to all stages of primary open-angle glaucoma (POAG) and can be used as a standalone procedure or in combination with cataract surgery. Multiple studies, including prospective, long-term, and real-world have demonstrated the safety, effectiveness, and durability of the OMNI procedure in both standalone and combination cataract procedures. With over 300,000 procedures performed, OMNI has established itself as a leader in canal-based MIGS. The introduction of OMNI Edge expands the OMNI product family while maintaining the availability of OMNI, ensuring surgeons have access to both technologies to meet their unique surgical preferences and patient needs. OMNI Edge is only available in the United States. Recent Insider Transactions • Apr 06
Co-Founder recently sold US$56k worth of stock On the 1st of April, Paul Badawi sold around 24k shares on-market at roughly US$2.30 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$73k. Paul has been a net seller over the last 12 months, reducing personal holdings by US$329k. Recent Insider Transactions Derivative • Apr 02
Co-Founder notifies of intention to sell stock Paul Badawi intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of April. If the sale is conducted around the recent share price of US$2.30, it would amount to US$56k. For the year to December 2020, Paul's total compensation was 16% salary and 84% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Paul's direct individual holding has increased from 5.16m shares to 6.03m. Company insiders have collectively sold US$3.3m more than they bought, via options and on-market transactions in the last 12 months. New Risk • Mar 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 6.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$62m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$233k sold). Price Target Changed • Mar 06
Price target decreased by 20% to US$3.50 Down from US$4.35, the current price target is an average from 6 analysts. New target price is 41% above last closing price of US$2.49. Stock is down 46% over the past year. The company is forecast to post a net loss per share of US$1.16 next year compared to a net loss per share of US$1.03 last year. Reported Earnings • Mar 06
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: US$1.03 loss per share (improved from US$1.14 loss in FY 2023). Revenue: US$79.9m (down 1.5% from FY 2023). Net loss: US$51.5m (loss narrowed 7.3% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.2%. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 06
Sight Sciences Provides Earnings Guidance for Full Year 2025 Sight Sciences provided earnings guidance for full year 2025. The company expects its revenue for full year 2025 to range from $70.0 million to $75.0 million, representing a 6% to 12% decline compared to full year 2024 revenue. Tillkännagivande • Feb 20
Sight Sciences, Inc. to Report Q4, 2024 Results on Mar 05, 2025 Sight Sciences, Inc. announced that they will report Q4, 2024 results After-Market on Mar 05, 2025 Recent Insider Transactions • Jan 23
Co-Founder recently sold US$73k worth of stock On the 16th of January, Paul Badawi sold around 25k shares on-market at roughly US$2.92 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$2.1m. Paul has been a net seller over the last 12 months, reducing personal holdings by US$337k. Recent Insider Transactions Derivative • Jan 17
Co-Founder notifies of intention to sell stock Paul Badawi intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of January. If the sale is conducted around the recent share price of US$2.92, it would amount to US$73k. For the year to December 2020, Paul's total compensation was 16% salary and 84% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Paul's direct individual holding has decreased from 5.76m shares to 5.70m. Company insiders have collectively sold US$3.3m more than they bought, via options and on-market transactions in the last 12 months. Price Target Changed • Jan 15
Price target decreased by 12% to US$4.62 Down from US$5.26, the current price target is an average from 5 analysts. New target price is 49% above last closing price of US$3.11. Stock is down 41% over the past year. The company is forecast to post a net loss per share of US$1.04 next year compared to a net loss per share of US$1.14 last year. Tillkännagivande • Jan 15
Sight Sciences Announces Earnings Guidance for Fourth Quarter and Full Year Ended December 31, 2024 Sight Sciences announced earnings guidance for Fourth Quarter and full year ended December 31, 2024. Fourth quarter 2024 total revenue is expected to be in the range of $18.9 million to $19.1 million, an increase of 1% at the estimated midpoint compared to the prior year period.
Full year 2024 total revenue is expected to be in the range of $79.7 million to $79.9 million, a decrease of 2% at the estimated midpoint compared to the prior year. Tillkännagivande • Jan 08
Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone Omni Surgical System in Managing Primary Open-Angle Glaucoma Sight Sciences, Inc. announced the publication of a landmark 36-month analysis evaluating the long-term effectiveness of the OMNI Surgical System in managing primary open-angle glaucoma ("POAG"). This study, in press in the American Journal of Ophthalmology and based on data from the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight), presents compelling evidence supporting the sustained benefits of standalone canaloplasty and trabeculotomy with OMNI, independent of cataract surgery. This real-world study, led by Nathan M. Radcliffe, MD, of Mount Sinai School of Medicine in New York City, evaluated 230 eyes of 196 patients with POAG through up to 36 months. The results demonstrate clinically and statistically significant reductions in intraocular pressure ("IOP") through up to 36 months postoperatively, with mean reductions ranging from 5.6 to 7.1 mmHg. The study also reports a statistically significant decrease in medication use through 18 months. Eyes with lower baseline IOP experienced medication reduction through 36 months. This prospective, observational cohort study of the procedure drew data from the IRIS Registry, the first comprehensive eye disease clinical registry in the United States. Launched in 2014, it has amassed over 851 million patient encounters and 80 million unique de-identified patients from nearly 30 electronic health records systems (EHRs) and 15,000 ophthalmologists and other eye care professionals across the U.S., as of July 1, 2024. This study provides invaluable insights into the real-world effectiveness of OMNI, offering a crucial data-driven resource for ophthalmologists seeking to improve outcomes for patients with POAG. Price Target Changed • Dec 12
Price target decreased by 8.1% to US$5.02 Down from US$5.46, the current price target is an average from 5 analysts. New target price is 35% above last closing price of US$3.72. Stock is up 9.1% over the past year. The company is forecast to post a net loss per share of US$1.05 next year compared to a net loss per share of US$1.14 last year. Recent Insider Transactions • Nov 24
Independent Chairman recently sold US$2.1m worth of stock On the 21st of November, Staffan Encrantz sold around 552k shares on-market at roughly US$3.73 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite the recent sale, Staffan has been a net buyer over the last 12 months, purchasing a net total of US$200k worth of shares. Reported Earnings • Nov 08
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2024 results: US$0.22 loss per share (improved from US$0.27 loss in 3Q 2023). Revenue: US$20.2m (flat on 3Q 2023). Net loss: US$11.1m (loss narrowed 15% from 3Q 2023). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates by 3.5%. Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Tillkännagivande • Nov 08
Sight Sciences, Inc. Announces Executive Appointments Sight Sciences, Inc. announced the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a consultant to help ensure a smooth transition. Dr. Raheja has more than 35 years of experience in ophthalmology medical device innovation, overseeing global ophthalmic R&D organizations responsible for bringing over 70 ophthalmic innovations to market. Over the past 18 months, Dr. Raheja has been advising emerging ophthalmic companies and not-for-profit entrepreneurial institutions. His most recent corporate roles include Head of Surgical Vision R&D at Johnson &Johnson Vision and Global Head of Corneal &Cataract R&D at Abbott Medical Optics, spanning over a 14-year period, which ended in April 2023. Prior to those roles, he served as Chief Technology Officer for CIBA Vision and as President and Chief Operating Officer of Hill Top Research, Inc. Dr. Raheja began his career at Bausch & Lomb in R&D where he held a number of leadership positions, including Vice President, Research Development & Engineering, and Vice President, New Product &New Business Development. Dr. Raheja holds a Ph.D. from the University of Massachusetts and an Executive M.B.A. from Boston University. Mr. Taylor has nearly 25 years of experience in medical and energy technology development and operations, overseeing innovation, product development, and manufacturing. He most recently served as Chief Executive Officer at NEXT Energy Technologies, where he initially joined as Executive Vice President, Engineering in 2021. Prior to this role, Mr. Taylor co-founded Inogen, Inc., where he spent over 20 years and was instrumental in developing and scaling a line of innovative respiratory medical devices to $350 million in annual sales. His last role at Inogen was Executive Vice President, Engineering. Mr. Taylor received a B.S. in microbiology from the University of California, Santa Barbara. 
